Pregene Biopharma is a leading enterprise in the field of cell and gene therapy, established in 2012. The company has developed a comprehensive platform for the research and industrialization of cell drugs, which includes several advanced technologies. Among these are the iPSCs (induced pluripotent stem cells) reprogramming and multi-gene editing platform, which allows for the generation of high-quality iPSCs from non-invasive sources such as blood or urine. This technology is pivotal for disease modeling, drug screening, and the development of therapeutic applications. Additionally, Pregene has established a nano-antibody screening platform that leverages the unique properties of heavy-chain antibodies, known for their stability and high specificity, making them suitable for use in CAR-T cell therapies.

The company also focuses on the development of immune cell drug discovery platforms and has capabilities in plasmid and viral vector process development and production. Their cell process development platform supports various automated and semi-automated systems for cell culture, separation, and sorting, enhancing the efficiency of CAR-T and CAR-NK cell preparations. Pregene's innovative approach and extensive research investment have positioned it as a significant player in the biopharmaceutical industry, with a robust pipeline of products aimed at addressing unmet medical needs.

China

Shenzhen Pregin Biopharmaceutical Co., Ltd. is a national high-tech enterprise, Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Technology Research Center, and Shenzhen Special New Enterprise. Investor shareholders include the National Small and Medium Enterprises Development Fund and the National Science and Technology Commission of the Chinese Academy of Sciences. Jiahe Fund, Haier Capital, Shenzhen Capital Group, Winbond Health ( 002004), etc. It has been deeply involved in the field of cell and gene therapy drugs for many years.

Pregene Biopharma

Company Details